FDA Lifts Partial Clinical Hold on Phase 1 Trial of MT-0169

The FDA has removed a partial clinical hold that had been placed on a phase 1 trial investigating the safety and efficacy of MT-0169 as a potential therapeutic option in patients with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma.

Related Keywords

Eric Poma , Molecular Templates Inc , , Molecular Templates , Nct0401713 , Mt 0169 , Patients With Relapsed Or Refractory Multiple Myeloma , Non Hodgkin Lymphoma , Phd , Nc ,